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Recessive modelsAbstract The fat mass and obesity-associated (FTO) gene is recognized as the strongest predictor
of obesity related traits such as insulin sensitivity and plasma glucose. The aim of this study was to
investigate the association of the FTO rs17817449 genetic variant (G > T) polymorphism with risk
of insulin resistance (IR) among Egyptian women. The variants in FTO rs17817449 were genotyped
in 301 Egyptian women comprising two study groups, 150 women with IR and 151 healthy controls.
The polymorphism of FTO rs17817449 was tested for association with IR. The frequencies of the
FTO genotypes differed significantly between IR patients and healthy controls. Results revealed a
significant association of TT genotype (OR, 2.33; 95% CI, 1.38–3.92; p= .001) and T-allele (OR,
1.55; 95% CI, 1.11–1.72; p .007) with IR. BMI, waist circumference, waist to hip and, body fat %
were the highest in homozygotes TT genotype and the lowest in GG homozygotes in IR women but
not observed in control subjects. Moreover, other abnormal metabolic risk parameters were signif-
icantly higher in TT carriers compared to GT and GG carriers in IR group. Association between
FTO SNP (rs17817449) and IR was observed under recessive model.
Conclusion: The present study suggests that FTO rs17817449 may have an important role in
development of IR in Egyptian women.
 2016 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Large energy intake and low physical action are major causes
of obesity on a population level, but studies on twins have
obviously established that obesity also has an importantgenetic component of 70% [15]. Several genome wide associa-
tion studies identified variants in the FTO (fat mass and obe-
sity associated) gene to be associated with body mass index
(BMI) [3,2]. Fat mass and obesity-associated FTO gene stands
out as the most vigorous and significant genetic contributor to
polygenic obesity [22,10].
For several decades, obesity and type 2 diabetes mellitus
(T2D) have been worldwide issues because of their alarming
increased prevalence and their associated morbidity (mainly
190 M.E. Zaki et al.essential hypertension, dyslipidemia, cardiovascular diseases)
and mortality. Over the last three decades, the prevalence of
overweight and obesity have increased rapidly and the World
Health Organization (WHO) estimates that 1.6 billion adults
were overweight and 400 million were obese which are pre-
dicted to rise.
The association of FTO single nucleotide polymorphisms
(SNPs) was confirmed with obesity in French Caucasians
[20] and with BMI, hip circumference, and weight in Sardini-
ans, European Americans, and Hispanic Americans but not
African Americans [20]. The role of FTO gene in type 2 dia-
betes is less clear, as other genome-wide association studies
have shown that SNPs in the gene were not associated with
type 2 diabetes in French Caucasian subjects [21], Finnish indi-
viduals [19], or in a combination of Finnish and Swedish sam-
ples [18]. Waist circumference was also strongly associated
with FTO genotype, as described in other studies [21,19].
The aim of the present was to assess the association of the
FTO SNP (rs17817449) with measures of obesity and insulin
resistance (IR) risk in the Egyptian women.
2. Materials and methods
The variants in FTO SNPs (rs17817449) were genotyped in 301
females comprising two study groups: (1) a case group consist-
ing of 150 women with IR enrolled at the outpatient clinic of
Medical services unit of National Research Centre, Egypt.
(2) The control group comprising 151 of Egyptian females.
Subjects with overweight/obesity or chronic diseases were
excluded from the control group. All subjects provided written
informed consent. This study protocol was approved by the
ethics committee board of the National Research Centre of
Egypt (No. 10/223).
2.1. Genotyping
Genomic DNA was extracted from peripheral blood leuco-
cytes from the samples collected for the purpose of this study
using salting-out modified method [1]. The SNP variant
rs17817449 was genotyped by a PCR–RFLP method. The pri-
mers used were as follows (Forward) 5-0AGGACCTCC
TATTTGGGACA-30 and (reverse) 50AGCTTCCATGGCTA
GCATTA-30 [4].
Each PCR reaction contained 25ul final volumes consisting
of the following 250 ng genomic DNA, 200 uMdNTPS, 0.5
unit of DNA polymerase (DyNAZyme II, FINZYMES) and
20 pmol of each primer. The thermocycling conditions con-
sisted of initial denaturation at 94 C for 5 min followed by
40 cycles of 30 s at 94 C, 30 s at 57 C, and for 30 s at
72 C, followed by final extension step consisted of 15 min at
72 C. PCR products were digested with AlwNI restriction
endonuclease (Fermentas, Germany) overnight at 37 C, giv-
ing 240 bp-bp product whereas the GG was present and two
fragments of 216 and 24 bp when T allele was present and
220, 216 bp and 24 bp when the GT was present. The products
of the digest were then visualized on a 2.5% agarose gel stained
with ethidium bromide. Polymorphisms were confirmed by
sequencing analysis and analytical validity was analyzed.
To ensure the accuracy of genotyping, one plate (containing
100 DNA samples) was analyzed twice within one week with
100% conformity.2.2. Anthropometry and laboratory methods
Anthropometric and body composition measurements were
performed with the subject wearing light clothing and without
shoes. For all subjects, body weight and height were measured
using a scale and a wall-mounted stadiometer to the nearest
0.5 kg and 0.5 cm respectively. Body mass index (BMI) was
computed as weight (in kilograms) divided by height (in
squared meters). Waist circumference (cm) was measured in
the middle between the 12th rib and the iliac crest, and hip cir-
cumference (cm) was measured around the buttocks, at the
level of the maximum extension. The waist-to-hip ratio was
then calculated. Skin fold thickness was measured using Hol-
tain skin fold Caliper, calibrated to 0.2 mm, but the measure-
ment can be conveniently estimated to the last completed
0.1 mm by the same investigator at the following sites: triceps
– half-way between the acromion and the olecranon; and sub-
scapular – 1 cm below the inferior angle of the scapula dial of
the caliper were illustrated and the sum of skinfold thickness
was calculated.
Body fat % was assessed by Tanita Body Composition
Analyzer (SC-330).
Blood pressure was measured three times and was averaged
for analysis. Fasting plasma glucose and insulin were measured
by enzymatic colorimetric methods using a Hitachi auto ana-
lyzer 704 (Roche Diagnostics Switzerland).
Insulin resistance was then determined by the Homeostasis
Model Assessment of Insulin Resistance (HOMA-IR) calcu-
lated as the product of the fasting plasma insulin level (lU/
mL) and the fasting plasma glucose level (mmol/L), divided
by 22.5.
HOMA-IR more than 3.4 was used for diagnosis of insulin
resistance in the present study.
2.3. Statistical analyses
All clinical data were expressed as mean ± SD. The distribu-
tions of the variables were examined using the Kolmogorov–
Smirnov test. Some discreet and continuous variables showed
skewed distribution, thus we applied nonparametric tests to
compare the differences between groups: Mann–Whitney U
test. Comparison of means between FTO genotypes was
tested. We used least squares means to evaluate potential asso-
ciations between FTO polymorphisms and obesity measures as
continuous traits. Differences in anthropometric and meta-
bolic measures were analyzed with ANOVA.
Genotype and allele distribution was compared between IR
and control subjects using 2 test, the odds ratios (ORs) and
95% confidence intervals (CIs) were also estimated.
Pearson’s chi square-test (2 d.f) was applied to test for devi-
ation from Hardy–Weinberg equilibrium in both the case and
control groups. Analysis of variance (ANOVA) followed by
Fisher’s post hoc PSLD test was used in order to examine obe-
sity related phenotypes for differences between genotype
groups assuming a recessive model and adjusting for signifi-
cant covariates.
All P-values reported are from two-sided tests and signifi-
cance was set at p< 0.05.
All statistical analyses were performed applying SPSS 16.0
package for Windows (SPSS Inc., Chicago, IL).
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The frequencies of the FTO genotypes differed significantly
between IR patients and healthy controls. The frequency of
the GG, GT, and TT genotypes were 31.13, 49.01, 19.86, in
control group and 26, 37.33, and 36.66 in IR group (Table 1).
We therefore studied the association of FTO variants with
metabolic parameters in IR patients and in controls. The
FTO genotypic distribution did not differ from the expected
values of the Hardy–Weinberg equilibrium. The FTO
rs17817449 showed an association with IR, 36.66% of cases
were TT-homozygote as compared to 19.86% of the control
subject (p< .001). Results revealed a significant association
of TT genotype (OR, 2.33; 95% CI, 1.38–3.92; p= .001) and
T-allele (OR, 1.55; 95% CI, 1.12–2.14; p .007) with IR.
Association of BMI, waist circumference and WHR and
skin fold thickness with the FTO rs17817449 genotypes in
IR patients and controls are shown in Table 2. The mean
BMI for IR cases was 30.3 ± 2.11 (kg/m2), and ranged 29–
33 (kg/m2), their mean age was 28.8 ± 1.30 years. Control
group had normal weight and their BMI was 22.3 ± 3.12.
The TT carriers had significantly higher values of BMI, waist
circumference, waist to hip ratio and skin folds values com-
pared to GT and GG carriers among IR cases; however this
association was not significant in the control group.
Table 3 shows Association of BMI, waist circumference,
WHR and body fat% with the FTO rs17817449 genotypes in
IR patients and controls. Analysis showed that TT carriers
had significant higher levels of SBP, DBP, fasting glucose,
insulin, HOMA-IR levels and body fat% than GT and GG
genotypes in IR group. However, no significant difference
was found in the control group.Table 1 Genotype and allele frequency of FTO SNPs (rs17817449)
Genotype Controls (n= 151) n (%) IR (n=
GG 47 (31.13) 39 (26%
GT 74 (49.01) 56 (37.3
TT 30 (19.86%) 55 (36.6
Allele
G 168 (55.62) 134 (44
T 134 (44.37%) 166 (55
Table 2 Mean of BMI, waist circumference, WHR and sum of ski
N % Controls (n= 151)
BMI (kg/m2) Waist (
GG 47 31.13 20.3 ± 3.11 76.91 ±
GT 74 49.01 22.34 ± 4.15 78.3 ±
TT 30 19.86 24.34 ± 2.13 78.9 ±
p= 0.0 6 p= 0.0
IR (n= 150)
GG 39 26 29 ± 3.51 85.91 ±
GT 56 37.33 30.3 ± 3.11 86.87 ±
TT 55 36.66 33.34 ± 2.10 122.3 ±
p= 0.0 2 p= 0.0
p 6 0.05 for ANOVA between genotypes in controls and IR cases.4. Discussion
In the present study, we confirmed the association of FTO
rs17817449 with IR and metabolic risk factors among Egyp-
tian women. The FTO gene variants were primarily described
to be associated with BMI levels in Caucasian studies, with
potentially sex specific effects. It is possible that the part of
the FTO risk associated with IR development is caused by ele-
vated BMI, in the current study the mean BMI values of IR
patients significantly increased compared to controls. The
association between IR and elevated BMI has been observed
in this study which is in agreement with several previous stud-
ies [3,2,1]. The present study suggests that both obesity and
genetic risk factors contribute to IR risk and both are of high
importance.
Obesity is a major health problem in recent years, and obe-
sity prevalence increased dramatically over the last decades.
Generally, obesity results from the interactions between
unhealthy life style (abundant energy intake and low physical
activity) and genetic predispositions. Among the newly
detected genes, particular interest is focused on the FTO gene,
the first locus unequivocally associated with BMI values.
The FTO gene is one of the few genes to show consistent
association with obesity as in Asian [13,16] and African popu-
lations [8]. The genome-wide association studies analyzed the
variants rs9939609, rs1421085 and rs17817449, and alleles A
(rs9939609), C (rs1421085), and G (rs17817449) found strong
association with obesity phenotypes. It has been shown that
all three variants are in almost complete linkage disequilib-
rium. The FTO gene codes for a 2-oxoglutarate-dependent-n
ucleicacid demethylase and is widely expressed in human tis-
sues [7]. Moreover, FTO variants could enhance the risk ofgene polymorphism in controls and IR subjects.
150) n (%) p-Value OR (95% CI)
) Reference Reference
3%) 0.22 1.22 (0.76–1.90)
6%) .001 2.33 (1.38–3.92)
.66%) Reference Reference
.33%) .007 1.55 (1.12–2.14)
n folds by the FTO rs17817449 genotype in IR and controls.
cm) Waist to hip ratio Sum of skin folds (mm)
5.01 .76±.09 27.05 ± 5.07
5.61 .76±.15 28.11 ± 3.11
8.13 .77 ±.13 29.51 ± 5.14
7 p= 0.06 p= 0.07
4.88 .91±.08 31.55 ± 4.70
5.01 .94±.09 38.55 ± 5.17
4.11 .99 ±.13 43.55 ± 6.44
4 p= 0.05 p= 0.05
Table 3 Association of BMI, waist circumference, WHR and body fat% with the FTO rs17817449 genotypes in IR patients and
controls.
Variables IR Controls
GG n= 39 GT n= 56 TT n= 55 Recessive p-value GG n= 47 GT n= 74 TT n= 30 Recessive p-value
SBP (mmHg) 114.2 ± 5.2 134.4 ± 6.4 154.1 ± 7.7 .05 110.2 ± 5.2 111.4 ± 6.4 112.2 ± 6.7 .06
DBP (mmHg) 80.6 ± 11.7 85.5 ± 9.1 90.4 ± 7.2 .02 79.6 ± 8.7 81.5 ± 9.8 82.4 ± 7.2 .07
Glucose (mg/dl) 82.9 ± 9.8 87.6 ± 9.3 118.6 ± 9.3 .03 80.9 ± 9.8 81.61 ± 9.5 84.6 ± 8.3 .08
Insulin (lU/mL) 10.6 ± 6.9 12.4 ± 5.91 16.5 ± 5.1 .05 9.6 ± 3.9 10.41 ± 5.9 11.5 ± 5.8 .06
HOMA-IR 1.8 ± .1.1 2.4 ± .89 4.4 ± .82 .02 1.4 ± .1.2 2.3 ± .8 2.4 ± .9 .09
Body fat % 25.5 ± 4.7 33.5 ± 6.5 42.5 ± 5.5 03 20.5 ± 6.5 22.3 ± 6.5 23.5 ± 5.4 06
Recessive mode indicates TT vs. GT and GG for rs17817449.
SBP: systolic blood pressure; DBP: diastolic blood pressure; HOMA-IR: homeostasis model assessment insulin resistance; IR: insulin resistance.
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effect on DNA methylation (i.e. the epigenetic status of the
organism). Animal experiments show clearly that different
nutritional and lifestyle factors affect the methylation (epige-
netic) status of many genes, thus most likely also genes influ-
encing IR development and methylation therefore play a
significant regulatory role in the wide spectrum of human
diseases.
Our results confirm previous findings of the association of
FTO SNP (rs17817449) with several measures of adiposity
and metabolic risk parameters. Several publications have con-
firmed the influence of FTO polymorphisms on fat mass in dif-
ferent population samples [19,1]. Variants in the first intron of
the FTO gene were associated with the BMI in the Western
European and North American populations [9], but the Ocea-
nic populations [16], Chinese [11], or African Americans [10]
displayed no significant association between the FTO poly-
morphisms and BMI. SNPs in the FTO gene have recently
been associated with obesity-related phenotypes [21,5] and
type 2 diabetes [19]. The present study focused on FTOSNP
(rs17817449) to investigate its association with IR among
Egyptian women which was shown to be mediated by its effect
on obesity. We analyzed metabolic traits among the IR women
and found association between FTO (rs17817449) and obesity
parameters as well as metabolic risk parameters, such as sys-
tolic and diastolic blood pressure and HOMA-IR.
Previous genetic association-based studies have shown that
SNPs in the FTO gene are associated with increased body mass
index (BMI) [2,20,23] and/or other metabolic-related traits,
such as higher fasting insulin [6], glucose, triglycerides, lower
HDL cholesterol, waist circumference [4] and weight.
Meta-analysis investigated the associations between five
FTO polymorphisms (rs9939609, rs1421085, rs8050136,
rs17817449, and rs1121980) and obesity risk in 41,734 cases
and 69,837 controls from 59 studies, counting the cases and
control subjects from each study only once [17]. They found
significant evidence for a modest increase in the risk of obesity
associated with the five polymorphisms in various ethnic
populations.
Our results confirm previous studies that reported associa-
tions between FTO polymorphisms and obesity-related mea-
sures. The strength of the FTO genotype effect on BMI in
this study was similar to results of previous reports. Earlier
studies in whites found that each risk allele was associated with
a BMI increase between 0.4 and 0.7 kg/m2, and homozygotesfor the risk allele were approximately 0.9–1.2 kg/m2 heavier
than those without a risk allele [12].
Egypt and the countries of the Middle East in general, are
typical of many middle income developing countries that have
experienced a rapid rise in the prevalence of obesity. Obesity in
the Eastern Mediterranean Region has reached ‘alarming
levels’ according to the World Health Organization [20]. Mar-
torell et al. [14] reported that women in Egypt have the highest
proportion of overweight (31.7%), as well as the highest pro-
portion of obesity (20.1%). FTOSNP (rs17817449) the present
study detected strong associations between FTO variants and
measures of obesity in IR patients which is similar to results
of previous reports [3]. This is the first study indicating major
differences with regard to the effect of this SNP on the preva-
lence of IR as well as for the associated phenotypes in Egyp-
tian women.
In conclusion, the present study suggests that FTO variants
play an important role in the adiposity measures in Egyptian
women and have an indicative value for predicting IR
development.
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